<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9854587</article-id><article-id pub-id-type="doi">10.3390/antibiotics12010035</article-id><article-id pub-id-type="publisher-id">antibiotics-12-00035</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Newly Discovered Mechanisms of Antibiotic Self-Resistance with Multiple Enzymes Acting at Different Locations and Stages</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiaorong</given-names></name><xref rid="af1-antibiotics-12-00035" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7263-522X</contrib-id><name><surname>Pan</surname><given-names>Hai-Xue</given-names></name><xref rid="af1-antibiotics-12-00035" ref-type="aff">1</xref><xref rid="af2-antibiotics-12-00035" ref-type="aff">2</xref><xref rid="c1-antibiotics-12-00035" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Gong-Li</given-names></name><xref rid="af1-antibiotics-12-00035" ref-type="aff">1</xref><xref rid="af2-antibiotics-12-00035" ref-type="aff">2</xref><xref rid="c1-antibiotics-12-00035" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sabatier</surname><given-names>Jean-Marc</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-12-00035"><label>1</label>School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub-Lane Xiangshan, Hangzhou 310024, China</aff><aff id="af2-antibiotics-12-00035"><label>2</label>State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200032, China</aff><author-notes><corresp id="c1-antibiotics-12-00035"><label>*</label>Correspondence: <email>panhx@sioc.ac.cn</email> (H.-X.P.); <email>gltang@sioc.ac.cn</email> (G.-L.T.)</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2023</year></pub-date><volume>12</volume><issue>1</issue><elocation-id>35</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>13</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Self-resistance determinants are essential for the biosynthesis of bioactive natural products and are closely related to drug resistance in clinical settings. The study of self-resistance mechanisms has long moved forward on the discovery of new resistance genes and the characterization of enzymatic reactions catalyzed by these proteins. However, as more examples of self-resistance have been reported, it has been revealed that the enzymatic reactions contribute to self-protection are not confined to the cellular location where the final toxic compounds are present. In this review, we summarize representative examples of self-resistance mechanisms for bioactive natural products functional at different cell locations to explore the models of resistance strategies involved. Moreover, we also highlight those resistance determinants that are widespread in nature and describe the applications of self-resistance genes in natural product mining to interrogate the landscape of self-resistance genes in drug resistance-related new drug discovery.</p></abstract><kwd-group><kwd>self-resistance</kwd><kwd>natural products</kwd><kwd>biosynthetic gene clusters</kwd><kwd>temporal-spatial shielding</kwd><kwd>intracellular multi-level resistance</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>31930002</award-id><award-id>21621002</award-id><award-id>32070065</award-id></award-group><funding-statement>This research was funded by National Natural Science Foundation of China (31930002, 21621002 and 32070065).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-12-00035"><title>1. Introduction</title><p>Natural products are small chemical compounds derived from secondary metabolites of animals, plants, and microorganisms with an array of biological activities. Since the discovery and clinical use of penicillin and streptomycin [<xref rid="B1-antibiotics-12-00035" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-12-00035" ref-type="bibr">2</xref>], natural products have been an important source of drugs and play a critical role in modern medicine and agricultural industries [<xref rid="B2-antibiotics-12-00035" ref-type="bibr">2</xref>]. However, widespread use and misuse of these small chemical compounds has led to the rising emergence of antibiotic resistance, resulting in the gradual loss of efficacy of antibiotics in clinic and natural environment. Antibiotic resistance has become one of the greatest public health threats that humans will have to face in the coming decades [<xref rid="B3-antibiotics-12-00035" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-12-00035" ref-type="bibr">4</xref>]. According to a report from the UK government, the death toll caused by antibiotic resistance is estimated to be up to 10 million per year by 2050, with a cost of drug resistance to $100 trillion [<xref rid="B5-antibiotics-12-00035" ref-type="bibr">5</xref>]. Therefore, there is an urgent need for uncovering the resistance mechanisms in pathogens and developing new compounds with novel modes of action [<xref rid="B6-antibiotics-12-00035" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-12-00035" ref-type="bibr">7</xref>,<xref rid="B8-antibiotics-12-00035" ref-type="bibr">8</xref>].</p><p>Generally, the clinical antibiotic resistance in human pathogens belongs to acquired resistance, with only a small fraction under the category of innate resistance. The origins of these acquired resistance genes have been traced to antibiotic-producers in natural environments [<xref rid="B9-antibiotics-12-00035" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-12-00035" ref-type="bibr">10</xref>]. In antibiotic-producing microbes, self-resistance is a prerequisite for the synthesis of antibiotics [<xref rid="B11-antibiotics-12-00035" ref-type="bibr">11</xref>]. Antibiotic biosynthetic gene clusters (BGCs) contain one or more resistance genes to achieve self-protection, and these genes are considered to be the reservoirs of resistance genes, which may transfer to human pathogens by conjugation, transformation or transduction [<xref rid="B9-antibiotics-12-00035" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-12-00035" ref-type="bibr">10</xref>,<xref rid="B12-antibiotics-12-00035" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-12-00035" ref-type="bibr">13</xref>]. Consequently, the elucidation of self-resistance mechanisms from antibiotic-producing microbes will not only reveal the action model of antibiotics and guide the discovery of new natural products, but also provide key clues for the studies of clinical antibiotic resistance [<xref rid="B8-antibiotics-12-00035" ref-type="bibr">8</xref>,<xref rid="B10-antibiotics-12-00035" ref-type="bibr">10</xref>,<xref rid="B13-antibiotics-12-00035" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-12-00035" ref-type="bibr">14</xref>].</p><p>To avoid suicide, antibiotic-producers have developed several mechanisms, including efflux pumps, chemical modification, prodrugs, compound sequestration, (sub)cellular location, target modification, and damage repair to shield the toxicity of antibiotics, thereby achieving self-protection [<xref rid="B6-antibiotics-12-00035" ref-type="bibr">6</xref>]. Different strategies are adapted depending on the structure of antibiotics, molecular target and producer species [<xref rid="B8-antibiotics-12-00035" ref-type="bibr">8</xref>]. For instance, within the enediyne producers, apoproteins are known to afford self-protection to the producers by binding the nine-membered enediyne chromophore, whereas the strategies of chemical modification guided by self-sacrifice proteins and sequestration mediated by drug binding proteins are utilized for the detoxification of ten-membered enediynes [<xref rid="B15-antibiotics-12-00035" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-12-00035" ref-type="bibr">16</xref>]. To prevent self-harm from bleomycin, its producer <italic toggle="yes">Steptomyces verticillus</italic> employs bleomycin N-acetylation and sequestration mechanisms to protect itself. The antitumor agent mitomycin C producer, <italic toggle="yes">Steptomyces lavendulae</italic>, has developed several mechanisms, including prodrug, efflux pump, drug sequestration, and reoxidation of the active reduced mitomycin C to ensure self-resistance [<xref rid="B15-antibiotics-12-00035" ref-type="bibr">15</xref>].</p><p>With sustained advances in the study of self-resistance mechanisms, researchers have found that the assembly of antibiotics and self-resistance do not always occur at the same cellular location. In some cases, self-resistance is achieved through enzymatic reaction occurring at different timing and location [<xref rid="B17-antibiotics-12-00035" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-12-00035" ref-type="bibr">19</xref>]. Although the self-protection mechanisms in antibiotic-producing microbes and application of self-resistance genes in natural product mining have been described in previous reviews [<xref rid="B6-antibiotics-12-00035" ref-type="bibr">6</xref>], the topic of self-resistance in microbes that synthesized final active drugs at different cell locations has never before been reviewed in its entirety. In addition, self-resistance genes that widely prevalent in nature were not described in previous reviews. Therefore, this contribution will provide an overview of newly-discovered self-resistance enzymes for natural products functional at different cell locations, explore the models of resistance strategies involved, describe those resistance determinants that are widespread in nature and the applications in natural product mining, and interrogate the landscape of self-resistance genes in combating drug resistance and future applications in new drug discovery. The self-resistance genes were selected as the keywords for the search in Google Scholar from 2016 to 2022.</p><p>In this review, we focus on new representative examples (<xref rid="antibiotics-12-00035-f001" ref-type="fig">Figure 1</xref>) of self-resistance mechanisms of bioactive natural products, aiming to provide a perspective on the ties between toxic antibiotics and self-resistance from timing and location. We present two models of self-resistance strategies: temporal-spatial shielding and non-spatial shielding&#x02013;intracellular multi-level resistance. As for the intracellular multi-level resistance model, both of the enzymatic reactions catalyzed by resistance proteins and the assembly of toxic natural products occur inside cells. Instead, in the temporal-spatial shielding model, the final toxic compounds are produced extracellularly by secreted proteins, and self-resistance is achieved through enzymatic reactions occurring at different timing and location. Moreover, we also highlight those resistance determinants that are widely spread in bacteria and describe examples of the use of self-resistance genes to guide the discovery of new natural products. Taken together, we expect to provide some new insight on the role of resistance genes in natural product biosynthesis and in response to clinical resistance.</p></sec><sec id="sec2-antibiotics-12-00035"><title>2. Temporal-Spatial Shielding Resistance</title><p>A drug molecule does not function unless it binds to its target. Microbes that synthesize antibiotics have developed a defensive strategy characterized as temporal-spatial shielding in order to prevent their own cytotoxic molecules binding to the target within the cells. The temporal-spatial shielding is a derivative of a common prodrug strategy, and the most significant difference between them is the presence or absence of secreted protein responsible for inert drug activation. In temporal-spatial shielding mode, antibiotics are synthesized as inert drugs and then transported to the extracellular space, followed by activation with enzymatic reactions catalyzed by secreted proteins, which contributes to the spatial shielding of drug activity. Moreover, cytosol-located resistance proteins will immediately inactivate the pharmacophore of synthetic intermediate or detoxify the final active drug that entered into the cell via passive diffusion, thus protecting the antibiotic producing microorganisms from timing. In fact, similar space shielding patterns are occasionally adopted to biosynthesize some aminoglycoside, macrolide and nonribosomal peptide antibiotics [<xref rid="B11-antibiotics-12-00035" ref-type="bibr">11</xref>,<xref rid="B20-antibiotics-12-00035" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-12-00035" ref-type="bibr">21</xref>]. In those cases, the activation of chemically modified prodrugs is catalyzed by membrane-bound enzymes via the hydrolysis of the modified groups such as phosphate groups and leader peptides. However, in the temporal-spatial shielding model, the inert prodrugs are transported across the membrane and further activated by the secreted proteins in extracellular space.</p><p>A well-studied example of temporal-spatial shielding mode is the NapW/NapU self-protection system in naphthyridinomycin (NDM, <bold>1</bold>) biosynthesis, in which NapU is responsible for extracellular activation and NapW contributes to intracellular detoxification [<xref rid="B17-antibiotics-12-00035" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>]. NDM, a member of tetrahydroisoquinoline alkaloids with complex hexacyclic structure, exhibits excellent antitumor and antimicrobial activities [<xref rid="B22-antibiotics-12-00035" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-12-00035" ref-type="bibr">23</xref>]. Its prominent biological activity is derived from the formation of electrophilic iminium species by eliminating C-7 hydroxyl, which covalently alkylates the N2 residue of guanine residing in the minor groove, forming DNA lesions that threaten cellular livelihood (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>A). In the NDM biosynthetic pathway, cytosol-located short-chain dehydrogenase/reductase NapW is responsible for reducing the hemiaminal pharmacophore of intermediate <bold>2</bold> to generate the non-toxic <bold>3</bold> (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>A), which ensures the harmlessness of following products and facilitates the biosynthetic process [<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>]. The resulting intermediate <bold>3</bold> is treated with a membrane protease NapG to produce the matured prodrug <bold>4</bold>, which is then transported out of the cell and activated by the secreted oxidoreductase NapU to generate the final product NDM (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>A). Moreover, NapU catalyzes the overoxidative inactivation of NDM into <bold>5</bold> to control the extracellular concentration of antibiotic and reduce damage to the producer cell [<xref rid="B17-antibiotics-12-00035" ref-type="bibr">17</xref>]. Beyond that, the re-entered final active drug NDM is also inactivated with the reductive reaction of NapW (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>A) [<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>]. The mechanism of NDM inactivation is completely different between intracellular and extracellular. The intracellular detoxification is achieved by reduction reaction and the extracellular by oxidation [<xref rid="B17-antibiotics-12-00035" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>], suggesting that new enzyme reactions are involved in pharmacophore modification beyond hydrolysis.</p><p>Compared to prokaryotes, the compartmentalized biosynthesis of natural products is more frequently used by eukaryotes to isolate the toxicity of substances, because the latter have discrete organelles to partition biosynthetic components orderly and efficiently [<xref rid="B24-antibiotics-12-00035" ref-type="bibr">24</xref>]. An excellent example is the compartmentalized biosynthesis of fungal mycophenolic acid, which sequesters the inhibition of mycophenolic acid on inosine-5-monophosphate dehydrogenase away from the nucleus of fungi, thereby ensuring the normal synthesis of DNA [<xref rid="B24-antibiotics-12-00035" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-12-00035" ref-type="bibr">25</xref>]. However, there are few reports on self-resistance mediated by enzyme-catalyzed temporal-spatial shielding in the biosynthesis of eukaryotic natural products. Recent studies of self-protection strategies against fungal macrolides revealed that this self-resistance mode is involved in the biosynthesis of A26771B [<xref rid="B19-antibiotics-12-00035" ref-type="bibr">19</xref>]. A26771B is a 16-membered fungal macrolide antibiotic isolated from <italic toggle="yes">Penicillium turbatum</italic>, and contains a succinate moiety and an unusual &#x003b3;-keto-&#x003b1;,&#x003b2;-unsaturated carboxyl, among which the &#x003b3;-keto group is the pharmacophore (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>B) [<xref rid="B26-antibiotics-12-00035" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-12-00035" ref-type="bibr">27</xref>,<xref rid="B28-antibiotics-12-00035" ref-type="bibr">28</xref>]. It exhibits prominent biological activity against Gram-positive bacteria and fungi, although with an unknown mode of action [<xref rid="B26-antibiotics-12-00035" ref-type="bibr">26</xref>]. To biosynthesize A26771B efficiently, its producer utilizes a strategy of intracellular reduction and extracellular oxidation for reversible conversion between ketone and alcohol, thus protecting itself from the cytotoxic effect of A26771B (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>B) [<xref rid="B19-antibiotics-12-00035" ref-type="bibr">19</xref>]. Intracellular acyltransferase BerkF catalyzes monosuccinylation of biosynthetic intermediate Berklactone C to generate the mature non-toxic prodrug Berkeleylactone E, which is then exported out of the cell and oxidized by secreted oxidoreductase BerkD to form the target antibiotic A26771B. Moreover, cytoplasmic short-chain reductase BerkC will reduce the &#x003b3;-keto group of antibiotic A26771B immediately once it enters into the host cell (<xref rid="antibiotics-12-00035-f002" ref-type="fig">Figure 2</xref>B). Therefore, the producer employs enzymatic reactions occurring at different timing and location to avoid self-destruction, which is appeared for the first time in fungal antibiotic biosynthesis. Given that the &#x003b3;-keto-&#x003b1;,&#x003b2;-unsaturated carboxyl serves as the pharmacophore for many fungal macrolide antibiotics, this reversible conversion between ketone and alcohol might be a generic self-resistance strategy in fungal macrolides biosynthesis. However, no more examples are currently available and therefore further studies will be necessary to verify this hypothesis.</p><p>The self-resistance strategy involving temporal-spatial shielding is widely recognized to apply a secreted protein that located in the extracellular space to catalyze the maturation of prodrugs, thereby sequestering the toxicity of the final products away from their intracellular targets. This spatial compartmentalization of biosynthetic steps is similar to the compartmentalized biosynthesis of fungal natural products, for which the cell membrane acts as the shield in isolation of toxic substances [<xref rid="B24-antibiotics-12-00035" ref-type="bibr">24</xref>]. Fungal cells comprise an additional endo-membrane system, whereas prokaryotes only contain an exo-membrane system. Therefore, in order to minimize the potential toxicity of natural products and control the efficiency of biosynthetic machinery, prokaryotes employ secreted proteins to complete the biosynthesis of final toxic products outside the cell. In addition, this temporal-spatial shielding mode of self-protection represents an evolutionary advantage and has been occasionally adopted by fungi to reduce the consumption of endogenous resources [<xref rid="B19-antibiotics-12-00035" ref-type="bibr">19</xref>].</p></sec><sec id="sec3-antibiotics-12-00035"><title>3. Intracellular Multi-Level Resistance</title><p>Aside from synthesized in the form of prodrugs, which are subsequently generated to active compounds during or after excretion, natural products are often directly synthesized in active forms inside the cell. Therefore, some producers would generate a multi-level resistance strategy composed of several resistance mechanisms to protect themselves from the toxicity of intracellular antibiotics. Here, we enumerate some recently reported examples, including bacteria that produce yatakemycin (YTM), azinomycin B (AZB), trioxacarcin A (TXNA)/LL-D49194 (LLD), capreomycin (CMN), and colibactins (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>).</p><p>YTM is a potent genotoxic agent belonging to the spirocyclopropylcyclohexadienone (SCPCHD) family natural products with remarkable cytotoxicity against various tumor cells and pathogenic fungi due to its DNA alkylating activity towards N3 position of adenine nucleobase and non-covalent CH-&#x003c0; interaction with deoxyribose group in DNA duplex [<xref rid="B29-antibiotics-12-00035" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-12-00035" ref-type="bibr">30</xref>,<xref rid="B31-antibiotics-12-00035" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-12-00035" ref-type="bibr">32</xref>,<xref rid="B33-antibiotics-12-00035" ref-type="bibr">33</xref>].To counter its toxicity, the YTM-producer <italic toggle="yes">Streptomyces</italic> sp. TP-3056 has developed a multi-level resistance strategy for self-protection, including efflux and chemical modification of YTM and repair of DNA (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>A). YtkR6 is homologous to the drug-resistance transporter ChaT1 [<xref rid="B34-antibiotics-12-00035" ref-type="bibr">34</xref>], and thereby considered to perform the efflux of YTM to extracellular space, and serve as the primary detoxification mechanism. In addition, GyrI-like protein YtkR7 will eliminate the DNA alkylating activity through hydrolysis of cyclopropane warhead to minimize the YTM concentration inside cell [<xref rid="B35-antibiotics-12-00035" ref-type="bibr">35</xref>]. Despite this, the active alkylating agent YTM can still covalently bind to the AT rich of DNA, thereby interrupting normal cellular process. DNA glycosylase YtkR2 is responsible for the remove of the 3-yatakemycinyladenine nucleobases through hydrolyzing the glycosidic bonds of YTM-DNA adducts, initiating the base excision repair pathway to complete the damage repair [<xref rid="B36-antibiotics-12-00035" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-12-00035" ref-type="bibr">37</xref>]. Structural analysis has revealed that, similar to <italic toggle="yes">Bacillus cereus</italic> AlkD [<xref rid="B33-antibiotics-12-00035" ref-type="bibr">33</xref>,<xref rid="B38-antibiotics-12-00035" ref-type="bibr">38</xref>], the DNA glycosylase YtkR2 adopts a non-base-flipping mechanism to excise 3-yatakemycinyladenine nucleobase [<xref rid="B33-antibiotics-12-00035" ref-type="bibr">33</xref>,<xref rid="B37-antibiotics-12-00035" ref-type="bibr">37</xref>]. The resulting AP site (apurinic/apyrimidinic site) is proposed to be processed by proteins TtkR3, TtkR4, and TtkR5, which are homologous to the enzymes involved in the BER system, including xanthine phosphoribosyl-transferase, mental-dependent TatD family of DNase and AP endonuclease, respectively [<xref rid="B39-antibiotics-12-00035" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-12-00035" ref-type="bibr">40</xref>]. Together, these six proteins form a multiple self-defense network to protect the producer from YTM toxicity. Given that the homologs of YtkR2 and YtkR7 were found in the producing strain of CC-1065 [<xref rid="B35-antibiotics-12-00035" ref-type="bibr">35</xref>,<xref rid="B37-antibiotics-12-00035" ref-type="bibr">37</xref>], another compound in SCPCHD family, it is likely that this self-defense network is a generic self-resistance strategy for SCPCHD natural product biosynthesis.</p><p>AZB, isolated from the culture medium of <italic toggle="yes">Streptomyces sahachiroi</italic>, is a genotoxic antibiotic that displays excellent antibacterial and antitumor activity by forming interstrand crosslinks (ICLs) in the duplex DNA sequence 5&#x02032;-d(GNPy)-3&#x02032; via alkylating the N7 nitrogen of purine residues [<xref rid="B41-antibiotics-12-00035" ref-type="bibr">41</xref>]. The AZB-producer <italic toggle="yes">S. sahachiroi</italic> is known to be protected by at least four proteins encoded by resistance genes, <italic toggle="yes">aziR</italic>, <italic toggle="yes">aziE</italic>, <italic toggle="yes">alkZ,</italic> and <italic toggle="yes">aziN</italic>, via drug sequestration, efflux, target protection and DNA damage repair, respectively (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>B) [<xref rid="B42-antibiotics-12-00035" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-12-00035" ref-type="bibr">43</xref>,<xref rid="B44-antibiotics-12-00035" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-12-00035" ref-type="bibr">45</xref>]. Among them, <italic toggle="yes">alkZ</italic> plays a dominant role because it is essential for AZB production [<xref rid="B43-antibiotics-12-00035" ref-type="bibr">43</xref>]. AziR, which is a drug-binding protein switched from aminoglycoside phosphotransferase, is responsible for binding to AZB to shield the drug activity [<xref rid="B42-antibiotics-12-00035" ref-type="bibr">42</xref>]. The transmembrane export protein encoded by <italic toggle="yes">aziE</italic> couples with the drug-binding protein AziR to form an effective efflux system to transport AZB outside of the cell, thereby maintaining a low concentration of the toxic compound [<xref rid="B43-antibiotics-12-00035" ref-type="bibr">43</xref>,<xref rid="B45-antibiotics-12-00035" ref-type="bibr">45</xref>]. Despite this, the intracellular residual drug might still cause DNA methylation to form AZB-adducts. In this case, glycosylase AlkZ of HTH_42 superfamily will confer the AZB resistance through target site protection and DNA damage repair. First, AlkZ nonspecifically binds to intact DNA with its helix-turn-helix motifs to block target sites. Upon the DNA ICLs are formed by AZB alkylation, glycosylase AlkZ binds to the damage sites structure-specifically and catalyzes the hydrolysis of N-glycosidic bond of AZB-adducts to remove the alkylated nucleobase, triggering the BER pathway to repair DNA damage [<xref rid="B43-antibiotics-12-00035" ref-type="bibr">43</xref>]. This is the first proposal of DNA glycosylase involved in the ICLs damage repair in prokaryotes. Although it is evolutionarily unrelated to the glycosylases AlkD/YtkR2, which is responsible for excision of bulky lesions, the crystal structure revealed that the glycosylase AlkZ uses a similar DNA-binding architecture and non-base-flipping mechanism to excise AZB-adducts [<xref rid="B44-antibiotics-12-00035" ref-type="bibr">44</xref>]. In addition to BER repair, later in 2020, He et al. discovered that the AZB-mediated ICLs can also be repaired by the structure-specific endonuclease AziN via triggering a nucleotide excision repair-like pathway [<xref rid="B45-antibiotics-12-00035" ref-type="bibr">45</xref>]. To be clear, knocking out <italic toggle="yes">aziN</italic> does not completely abolish the production of AZB, indicating that the repair pathway mediated by endonuclease AziN plays a secondary role compared with the BER pathway triggered by AlkZ. However, it is unclear when and how to recruit the endonuclease AziN to the damaged sites. In addition, whether there are direct or indirect interactions between the four resistance mechanisms remains unclear.</p><p>TXNA and LLD, two representative antibiotics of trioxacarcin family, are genotoxic polyketide natural products with prominent antimalarial, antibacterial, and antitumor activity [<xref rid="B46-antibiotics-12-00035" ref-type="bibr">46</xref>,<xref rid="B47-antibiotics-12-00035" ref-type="bibr">47</xref>]. To withstand the genotoxicity of TXNA and LLD [<xref rid="B48-antibiotics-12-00035" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-12-00035" ref-type="bibr">49</xref>], their producing bacteria have evolved drug efflux system and DNA damage repair proteins (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>C), which are encode by genes in the <italic toggle="yes">txn</italic> and <italic toggle="yes">lld</italic> biosynthetic clusters [<xref rid="B50-antibiotics-12-00035" ref-type="bibr">50</xref>,<xref rid="B51-antibiotics-12-00035" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-12-00035" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-12-00035" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-12-00035" ref-type="bibr">54</xref>]. The hypothetical MSF transmembrane export proteins encoded by <italic toggle="yes">txnRr1</italic> and <italic toggle="yes">txnRr2</italic> are supposed to play roles in the efflux of TXNA, and the DNA glycosylases encoded by <italic toggle="yes">txnU2</italic> and <italic toggle="yes">txnU4</italic> act on the TXNA-guanine adducts to trigger the BER pathway, providing self-protection to TXN toxicity [<xref rid="B54-antibiotics-12-00035" ref-type="bibr">54</xref>]. Similarly, the homologs of TxnRr1/Rr2 and TxnU2/U4 encoded by the biosynthesis gene cluster <italic toggle="yes">lld</italic> provide resistance to LLD for the producer [<xref rid="B54-antibiotics-12-00035" ref-type="bibr">54</xref>]. Intriguingly, although both TxnU/LldU and AlkZ are monofunctional DNA glycosylases of HTH_42 family, the former has a distinct catalytic motif relative to AlkZ, resulting in that TxnU/LldU exhibits no activity toward other bulky and crosslinking DNA adducts beyond TXNA/LLD-DNA lesions. Based on the crystal structure of TXNA-DNA, TXNA can not only alkylate DNA to form the bulky adducts, but also intercalate into the duplex DNA and extrude the nucleobase near the alkylating site out of the helix, resulting in an increased helical twist [<xref rid="B49-antibiotics-12-00035" ref-type="bibr">49</xref>]. It would be interesting to find whether TXNA/LLD-DNA lesions are also repaired by other enzymes or pathways, such as NER or endonuclease AziN reported in AZB biosynthesis [<xref rid="B45-antibiotics-12-00035" ref-type="bibr">45</xref>]. Therefore, more work is needed to elucidate the self-resistance system of TXNs.</p><p>CMNs represent a mixture of nonribosomal peptide antibiotics including CMN IA, IB, IIA and IIB that are second-line drugs for the treatment of multidrug-resistant tuberculosis [<xref rid="B55-antibiotics-12-00035" ref-type="bibr">55</xref>,<xref rid="B56-antibiotics-12-00035" ref-type="bibr">56</xref>]. These molecules bind to the bacterial ribosomes and inhibit the biosynthesis of proteins [<xref rid="B57-antibiotics-12-00035" ref-type="bibr">57</xref>]. CMN-producing strain <italic toggle="yes">Saccharothrix mutabilis</italic> subsp. <italic toggle="yes">capreolus</italic> possesses several self-resistance mechanisms to overcome the cytotoxicity (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>D). The <italic toggle="yes">cac</italic> gene, located far away from the CMN BGC, encodes an N-acetyltransferase that inactivates CMN IIA and IIB via acetylation of the <italic toggle="yes">&#x003b2;</italic>-lysine moiety [<xref rid="B58-antibiotics-12-00035" ref-type="bibr">58</xref>]. The second resistance gene was proposed to be <italic toggle="yes">cmnU</italic> within the BGC, deduced to encode a methyltransferase related to the KamB and KamC that confer resistance to kanamycin by methylating 16S rRNA. Consistent with this proposal, the expression of <italic toggle="yes">cmnU</italic> in <italic toggle="yes">Streptomyces lividans</italic> and <italic toggle="yes">Escherichia coli</italic> conferred high-level resistance to CMN and kanamycin [<xref rid="B58-antibiotics-12-00035" ref-type="bibr">58</xref>], although an in vitro assay of CmnU for rRNA methyltransferase activity was not performed. The third is the <italic toggle="yes">cph</italic> gene that plays a role in the phosphorylation of CMN IA and IIA at the Ser hydroxyl group, but not on CMN IB or IIB. Subsequent biochemical assays and structure analysis determined that the Cph exhibits a high binding affinity to both CMN IIA and IIB, and its expression confers <italic toggle="yes">E. coli</italic> resistance to CMN IIB, suggesting Cph also serves as an antibiotic sequester beyond phosphotransferase [<xref rid="B59-antibiotics-12-00035" ref-type="bibr">59</xref>]. Consequently, compared to general phosphotransferases, Cph adopts a dual mechanism to inactivate antibiotics by either chemical modification or physical sequestration. Besides drug modification and sequestration enzymes, the CMN BGC also contains a hypothetical MSF efflux protein that was deduced to transport the phosphorylated CMN, while the transportation has not been verified.</p><p>Colibactins are a group of genotoxic, nonribosomal peptide-polyketide secondary metabolites of gut-commensal <italic toggle="yes">E. coli</italic> that contain the <italic toggle="yes">pks</italic> island [<xref rid="B60-antibiotics-12-00035" ref-type="bibr">60</xref>,<xref rid="B61-antibiotics-12-00035" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-12-00035" ref-type="bibr">62</xref>]. These cryptic genotoxins have attracted continuous studies due to their close correlation to human health. They cause DNA double-strand breaks through DNA crosslinking or copper-mediated oxidative cleavage, leading to cell-cycle arrest and even cell death [<xref rid="B63-antibiotics-12-00035" ref-type="bibr">63</xref>,<xref rid="B64-antibiotics-12-00035" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-12-00035" ref-type="bibr">65</xref>]. To counter the cytotoxicity of colibactin, at least four colibactin-resistance determinants (<italic toggle="yes">clbN</italic>, <italic toggle="yes">clbB</italic>, <italic toggle="yes">clbM</italic> and <italic toggle="yes">clbS</italic>) are present in the <italic toggle="yes">pks</italic> biosynthetic cluster (<xref rid="antibiotics-12-00035-f003" ref-type="fig">Figure 3</xref>E). Nonribosomal peptide synthetases ClbN and ClbB install an N-acyl-D-asparagine prodrug motif at the N-terminus of colibactin to prevent the formation of the active imine moiety at the early stage of colibactin biosynthesis, thereby generating the inactive prodrug [<xref rid="B66-antibiotics-12-00035" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-12-00035" ref-type="bibr">67</xref>]. Subsequently, the resulting precolibactin will be transported into the periplasm by the 12-transmembrane MATE inner-membrane transporter ClbM [<xref rid="B68-antibiotics-12-00035" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-12-00035" ref-type="bibr">69</xref>,<xref rid="B70-antibiotics-12-00035" ref-type="bibr">70</xref>], where mature colibactin is generated via cleavage of prodrug structure with peptidase ClbP, followed by out membrane translocation [<xref rid="B67-antibiotics-12-00035" ref-type="bibr">67</xref>,<xref rid="B71-antibiotics-12-00035" ref-type="bibr">71</xref>]. Notably, knocking out <italic toggle="yes">clbM</italic> does not completely abolish the production of colibactin, indicating that precolibactin can also be exported across the cytoplasmic membrane by other means. The intracellular cyclopropane hydrolase encoded by <italic toggle="yes">clbS</italic> abrogates cytotoxicity of the offloaded intermediates or colibactin by converting the electrophilic cyclopropane into an innocuous hydrolase product [<xref rid="B72-antibiotics-12-00035" ref-type="bibr">72</xref>]. Interestingly, besides directly inactivating genotoxic cyclopropane, ClbS also functions as a DNA binding protein that protects the bacterial DNA from nucleolytic degradation [<xref rid="B73-antibiotics-12-00035" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-12-00035" ref-type="bibr">74</xref>]. However, the relationship between DNA binding activity and colibactin resistance remains obscure.</p></sec><sec id="sec4-antibiotics-12-00035"><title>4. Resistance Widespread in Nature</title><p>Self-resistance determinants are not confined to the antibiotic producers. Instead, some of them are widely prevalent in the clinical pathogens and environmental bacteria [<xref rid="B75-antibiotics-12-00035" ref-type="bibr">75</xref>]. Recent studies of self-resistance mechanisms against enediyne antitumor antibiotics revealed that an unprecedented sequestration mechanism for the anthraquinone-fused enediynes has been evolved in their producers and the homologs of these resistance elements are widely distributed in nature [<xref rid="B16-antibiotics-12-00035" ref-type="bibr">16</xref>]. Within the gene cluster of tiancimycin (<xref rid="antibiotics-12-00035-f004" ref-type="fig">Figure 4</xref>), resistance genes <italic toggle="yes">tnmS1</italic>, <italic toggle="yes">tnmS2</italic>, and <italic toggle="yes">tnmS3</italic> play a role in the sequestration of tiancimycin. The homologs of TnmS1, TnmS2, and TnmS3 are widespread in anthraquinone-fused enediynes producers and other bacteria, from different body sites, including the human microbiome [<xref rid="B16-antibiotics-12-00035" ref-type="bibr">16</xref>]. The expression of homologous genes from the gene clusters encoding enediyne biosynthesis has been reported to endow <italic toggle="yes">E. coli</italic> BL21(DE3) with cross-resistance to anthraquinone-fused enediynes, while the homologs from human microbiome confer specific resistance to tiancimycin A [<xref rid="B16-antibiotics-12-00035" ref-type="bibr">16</xref>]. These results further highlight that the resistance elements responsible for anthraquinone-fused enediynes sequestration are widely distributed in nature, although little is known about how these resistance genes disseminate in the environment. Similarly, homologous resistance genes encoding following enzymes are widespread in nature and perform conserved biological functions, such as GyrI-like cyclopropane hydrolases that mediate cyclopropyl moiety opening of DNA-alkylating agents YTM/CC-1065 [<xref rid="B35-antibiotics-12-00035" ref-type="bibr">35</xref>], AlbA-like drug-binding proteins that guide resistance to albicidin [<xref rid="B76-antibiotics-12-00035" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-12-00035" ref-type="bibr">77</xref>], and NapW-like short-chain dehydrogenase/reductase that catalyze hemiaminal pharmacophore inactivation for tetrahydroisoquinoline antibiotics (<xref rid="antibiotics-12-00035-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B18-antibiotics-12-00035" ref-type="bibr">18</xref>]. In addition to antibiotic resistance, non-antibiotic drug resistance is also widespread. As direct evidence for this conception, Acbk-like kinase, inactivating a clinically used non-antibiotic antidiabetic drug acarbose by phosphorylation, is widely distributed in the human gut and oral microbiome (<xref rid="antibiotics-12-00035-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B78-antibiotics-12-00035" ref-type="bibr">78</xref>]. The specific kinase AcbK derived from <italic toggle="yes">Actinoplanes</italic> sp. SE50/110, is located within the gene cluster for acarbose synthesis. It phosphorylates acarbose at the O6A hydroxyl and serves as the self-resistance mechanism for acarbose production [<xref rid="B79-antibiotics-12-00035" ref-type="bibr">79</xref>]. Recently, Donia et al. performed a metagenomics-based investigation of the human microbiome and found that homologues of AcbK are widespread in the bacteria from the human gut and oral microbiome and provide acarbose resistance, indicating the phosphorylation strategy of acarbose has disseminated in the human microbiome as a resistance mechanism [<xref rid="B78-antibiotics-12-00035" ref-type="bibr">78</xref>]. Therefore, research on these widely distributed resistance elements will contribute to predicting and combating clinical drug resistance.</p></sec><sec id="sec5-antibiotics-12-00035"><title>5. Resistance-Guided Natural Products Discovery</title><p>The rapid development of bioinformatics tools and genome sequencing technologies has brought a revolution in the discovery of natural products, leading to a transformation from traditional bioactivity-guided fractionation to modern genome-based target mining [<xref rid="B80-antibiotics-12-00035" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-12-00035" ref-type="bibr">81</xref>]. The enormous amount of genome data that is now available has revealed that microorganisms harbor more natural product BGCs than those observed under laboratory cultivation conditions, and most of them gene clusters encoding unknown products [<xref rid="B82-antibiotics-12-00035" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-12-00035" ref-type="bibr">83</xref>]. However, how to deal with the increasing BGCs and how to mine the desired products from the huge resources have become a major focus. Recently, researchers found that the self-resistance genes co-localized with BGCs can be used as a potential tool to link BGCs with molecular targets for mining natural products with desired activity (<xref rid="antibiotics-12-00035-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B8-antibiotics-12-00035" ref-type="bibr">8</xref>,<xref rid="B84-antibiotics-12-00035" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-12-00035" ref-type="bibr">85</xref>]. For example, Tang and coworkers successfully discovered a natural herbicide with a new mode of action from <italic toggle="yes">Aspergillus terreus</italic> by a putative self-resistance gene, <italic toggle="yes">astD</italic>, encoding a dihydroxyacid dehydratase (DHAD) homolog [<xref rid="B14-antibiotics-12-00035" ref-type="bibr">14</xref>]. The DHAD is an essential enzyme that catalyzes the last step of branched-chain amino acid biosynthesis, and is therefore effectively targeted for herbicide development [<xref rid="B14-antibiotics-12-00035" ref-type="bibr">14</xref>]. However, no compounds that target this enzyme have been reported in planta. Fungal genomes scanning of a DHAD homologue revealed that a BGC encoding a sesquiterpene cyclase homologue and a DHAD homologue was present in the genome of <italic toggle="yes">Aspergillus terreus</italic>. Subsequent experiments demonstrated that the aspterric acid encoded by this BGC is indeed a competitive inhibitor of DHAD and effectively functions as a herbicide, and the DHAD variant AstD functions as a self-resistance enzyme in the BGC for aspterric acid [<xref rid="B14-antibiotics-12-00035" ref-type="bibr">14</xref>]. Similarly, the M&#x000fc;ller group discovered a novel group of topoisomerase inhibitors, including pyxidicycline A and B, by putative self-resistance genes encoding topoisomerase-targeting pentapeptide repeat protein [<xref rid="B86-antibiotics-12-00035" ref-type="bibr">86</xref>]. Wright et al. identified the caseinolytic protease (ClpP) inhibitor clipibicyclene from <italic toggle="yes">Streptomyces cattleya</italic> using ClpP as putative antibiotic resistance gene [<xref rid="B87-antibiotics-12-00035" ref-type="bibr">87</xref>]. Ge et al. discovered a novel tetracycline, hainancycline, by using the common tetracycline antibiotics resistance enzyme TetR/MarR-transporter as probe [<xref rid="B88-antibiotics-12-00035" ref-type="bibr">88</xref>].</p><p>In addition to discovering natural products with desired activity, self-resistance genes can also be used in determining the biomolecular target of known antibiotics (<xref rid="antibiotics-12-00035-f006" ref-type="fig">Figure 6</xref>). For instance, the &#x003b2;-lactone obafluorin isolated from <italic toggle="yes">Pseudomonas fluorescens</italic> ATCC 39502 shows potent antibacterial activity against both Gram-positive and Gram-negative pathogens [<xref rid="B89-antibiotics-12-00035" ref-type="bibr">89</xref>]. The mechanism of action of obafluorin, however, was unknown as this molecule was reported to cause an unusual cell-elongation phenotype compared to other &#x003b2;-lactone antibiotics. During comparative genomic analysis of obafluorin BGCs, an open reading frame, <italic toggle="yes">obaO</italic>, was identified and speculated to be an immunity gene [<xref rid="B89-antibiotics-12-00035" ref-type="bibr">89</xref>]. ObaO was shown to be a homologue of threonyl-tRNA synthetase and conferred resistance to obafluorin-sensitive strains and obafluorin producer when expressed. Subsequently, in vitro enzyme assays demonstrated that the obafluorin did indeed fully inhibit <italic toggle="yes">E. coli</italic> threonyl-tRNA synthetase with an IC<sub>50</sub> of 92 &#x000b1; 21 nM, thus indicating the target of this compound [<xref rid="B89-antibiotics-12-00035" ref-type="bibr">89</xref>]. In another example, harzianic acid is a N-methylated tetramic acid isolated from <italic toggle="yes">Trichoderma harzianum</italic> in 1994. Although it displays excellent antifungal activity, including against plant pathogens <italic toggle="yes">Sclerotinia sclerotiorum</italic> and <italic toggle="yes">Rhizoctonia solani</italic>, the molecular target of harzianic acid remains unknown [<xref rid="B90-antibiotics-12-00035" ref-type="bibr">90</xref>]. Recently, Tang et al. discovered that the harzianic acid is an inhibitor of acetohydroxyacid synthase (AHAS, the first enzyme on branched-chain amino acid biosynthesis pathway), which was guided by a truncated AHAS homolog resided within the BGC that was demonstrated to be the self-resistance enzyme [<xref rid="B91-antibiotics-12-00035" ref-type="bibr">91</xref>]. A similar biomolecular target discovery scenario is also observed in determining the mode of action of polyketide rumbrins, which further revealed their promising potential to be HIV inhibitors [<xref rid="B92-antibiotics-12-00035" ref-type="bibr">92</xref>].</p><p>Although the above examples have successfully confirmed the potential of self-resistance genes in directed genome mining for natural products with known or predicted biomolecular targets, the development of compounds with novel mechanisms of action is also an urgent need to solve the ongoing antibiotic crisis. Recently, Wright et al. reported that the method of combining the absence of known self-resistance genes with phylogenetic analysis of biosynthetic genes could be effective in finding natural products with new modes of action [<xref rid="B93-antibiotics-12-00035" ref-type="bibr">93</xref>]. They applied this approach to the glycopeptide family of antibiotics and successfully discovered a novel functional class of glycopeptide antibiotics composed of complestatin and corbomycin (<xref rid="antibiotics-12-00035-f005" ref-type="fig">Figure 5</xref>), which have a new mechanism of action that inhibits peptidoglycan re-modelling. This research outcome again indicated that self-resistance determinants are useful for prioritizing BGCs than just function in the self-protection. Other examples of employing a self-resistance determinant in natural products discovery are reviewed elsewhere [<xref rid="B6-antibiotics-12-00035" ref-type="bibr">6</xref>,<xref rid="B8-antibiotics-12-00035" ref-type="bibr">8</xref>,<xref rid="B94-antibiotics-12-00035" ref-type="bibr">94</xref>]. Taken together, self-resistance genes can be a bridge between the bioactivity-guided and genome-based methods for natural products discovery. Studying the complex self-resistance strategies from a temporal-spatial shielding perspective will allow researchers to further understanding the evolutionary relationship between natural product biosynthesis and resistance, thereby facilitating discovery of new drug candidates with high activity.</p></sec><sec sec-type="conclusions" id="sec6-antibiotics-12-00035"><title>6. Conclusions and Perspective</title><p>Organisms that produce toxic natural products have evolved various self-resistance determinants in offensive and defensive contexts. According to the location where final toxic compounds are produced, we summarized two models that organisms utilize for self-protection, intending to provide a perspective on the ties between toxic antibiotic biosynthesis and self-resistance from spatial distribution. Research on self-resistance mechanisms extend well beyond revealing the origin of natural product resistance and predicting the action model of these molecules. In terms of bioengineering, a deep understanding of antibiotic resistance mechanisms is crucial for the efficient synthesis of target natural products and the development of next-generation antibiotics capable to overcome established clinical resistances. Additionally, determinants conferring self-protection in antibiotic producing organisms are considered to represent a major reservoir of resistance genes, which could disseminate into human pathogens by horizontal gene transfer [<xref rid="B13-antibiotics-12-00035" ref-type="bibr">13</xref>]. Reviewing self-resistance with a multi-dimensional perspective is therefore helpful to better cope with the increasing drug resistance in clinical settings. Moreover, regarding natural products mining, self-resistance proteins mutated from essential housekeeping enzymes have effectively served as a tool to link BGCs with molecular targets. However, using this strategy for genome mining might inevitably lead to the mining of results skewed to known compounds. The continued study of natural product biosynthesis and multi-dimensional self-resistance is required for mining desired compounds with higher accuracy. Taken together, self-resistance genes are expected to serve as models to predict and combat drug resistance in clinical settings and to be an effective bridge between the bioactivity-guided and genome-based methods for natural product discovery, thus facilitating discovery of new drug candidates. It is expected that more self-resistance determinants will be discovered to enrich our knowledge on the relationship between natural product toxicity and resistance genes and facilitate the discovery of new drug candidates to combat clinical resistance.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, X.C., H.-X.P. and G.-L.T.; literature search, X.C.; writing&#x02014;original draft preparation, X.C.; writing&#x02014;review and editing, X.C., H.-X.P. and G.-L.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-12-00035"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waksman</surname><given-names>S.A.</given-names></name>
<name><surname>Schatz</surname><given-names>A.F.</given-names></name>
<name><surname>Reynolds</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Production of antibiotic substances by actinomycetes</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2010</year><volume>1213</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05861.x</pub-id><?supplied-pmid 21175680?><pub-id pub-id-type="pmid">21175680</pub-id></element-citation></ref><ref id="B2-antibiotics-12-00035"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>D.J.</given-names></name>
<name><surname>Cragg</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Natural products as sources of new drugs from 1981 to 2014</article-title><source>J. Nat. Prod.</source><year>2016</year><volume>79</volume><fpage>629</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b01055</pub-id><?supplied-pmid 26852623?><pub-id pub-id-type="pmid">26852623</pub-id></element-citation></ref><ref id="B3-antibiotics-12-00035"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>E.D.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Antibacterial drug discovery in the resistance era</article-title><source>Nature</source><year>2016</year><volume>529</volume><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nature17042</pub-id><?supplied-pmid 26791724?><pub-id pub-id-type="pmid">26791724</pub-id></element-citation></ref><ref id="B4-antibiotics-12-00035"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beyer</surname><given-names>P.</given-names></name>
<name><surname>Moorthy</surname><given-names>V.</given-names></name>
<name><surname>Paulin</surname><given-names>S.</given-names></name>
<name><surname>Hill</surname><given-names>S.R.</given-names></name>
<name><surname>Sprenger</surname><given-names>M.</given-names></name>
<name><surname>Garner</surname><given-names>S.</given-names></name>
<name><surname>Sim&#x000e3;o</surname><given-names>M.</given-names></name>
<name><surname>Guerra</surname><given-names>R.</given-names></name>
<name><surname>Magrini</surname><given-names>N.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
</person-group><article-title>The drugs don&#x02019;t work: WHO&#x02019;s role in advancing new antibiotics</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31570-8</pub-id><?supplied-pmid 30064640?><pub-id pub-id-type="pmid">30064640</pub-id></element-citation></ref><ref id="B5-antibiotics-12-00035"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Neil</surname><given-names>J.O.</given-names></name>
</person-group><article-title>The Review on Antimocronial Resistance</article-title><comment>Available online: <ext-link xlink:href="https://amr-review.org" ext-link-type="uri">https://amr-review.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-10-01">(accessed on 1 October 2022)</date-in-citation></element-citation></ref><ref id="B6-antibiotics-12-00035"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almabruk</surname><given-names>K.H.</given-names></name>
<name><surname>Dinh</surname><given-names>L.K.</given-names></name>
<name><surname>Philmus</surname><given-names>B.</given-names></name>
</person-group><article-title>Self-resistance of natural product producers: Past, present, and future focusing on self-resistant protein variants</article-title><source>ACS Chem. Biol.</source><year>2018</year><volume>13</volume><fpage>1426</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b00173</pub-id><pub-id pub-id-type="pmid">29763292</pub-id></element-citation></ref><ref id="B7-antibiotics-12-00035"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>D.J.</given-names></name>
<name><surname>Cragg</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="B8-antibiotics-12-00035"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>N.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Recent developments in self-resistance gene directed natural product discovery</article-title><source>Nat. Prod. Rep.</source><year>2020</year><volume>37</volume><fpage>879</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1039/C9NP00050J</pub-id><pub-id pub-id-type="pmid">31912842</pub-id></element-citation></ref><ref id="B9-antibiotics-12-00035"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wencewicz</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Crossroads of antibiotic resistance and biosynthesis</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>3370</fpage><lpage>3399</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.06.033</pub-id><pub-id pub-id-type="pmid">31288031</pub-id></element-citation></ref><ref id="B10-antibiotics-12-00035"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>The antibiotic resistome: The nexus of chemical and genetic diversity</article-title><source>Nat. Rev. Microbiol.</source><year>2007</year><volume>5</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1614</pub-id><pub-id pub-id-type="pmid">17277795</pub-id></element-citation></ref><ref id="B11-antibiotics-12-00035"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cundliffe</surname><given-names>E.</given-names></name>
<name><surname>Demain</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Avoidance of suicide in antibiotic-producing microbes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2010</year><volume>37</volume><fpage>643</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1007/s10295-010-0721-x</pub-id><pub-id pub-id-type="pmid">20446033</pub-id></element-citation></ref><ref id="B12-antibiotics-12-00035"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Livermore</surname><given-names>D.</given-names></name>
</person-group><article-title>Can better prescribing turn the tide of resistance?</article-title><source>Nat. Rev. Microbiol.</source><year>2004</year><volume>2</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/nrmicro798</pub-id><?supplied-pmid 15035011?><pub-id pub-id-type="pmid">15035011</pub-id></element-citation></ref><ref id="B13-antibiotics-12-00035"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>E.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
</person-group><article-title>Antibiotic resistance mechanisms in bacteria: Relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2928</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02928</pub-id><?supplied-pmid 30555448?><pub-id pub-id-type="pmid">30555448</pub-id></element-citation></ref><ref id="B14-antibiotics-12-00035"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zang</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>S.</given-names></name>
<name><surname>Bat-Erdene</surname><given-names>U.</given-names></name>
<name><surname>Nguyen</surname><given-names>C.</given-names></name>
<name><surname>Gan</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.E.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Resistance-gene-directed discovery of a natural-product herbicide with a new mode of action</article-title><source>Nature</source><year>2018</year><volume>559</volume><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0319-4</pub-id><pub-id pub-id-type="pmid">29995859</pub-id></element-citation></ref><ref id="B15-antibiotics-12-00035"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galm</surname><given-names>U.</given-names></name>
<name><surname>Hager</surname><given-names>M.H.</given-names></name>
<name><surname>Van Lanen</surname><given-names>S.G.</given-names></name>
<name><surname>Ju</surname><given-names>J.</given-names></name>
<name><surname>Thorson</surname><given-names>J.S.</given-names></name>
<name><surname>Shen</surname><given-names>B.</given-names></name>
</person-group><article-title>Antitumor antibiotics: Bleomycin, enediynes, and mitomycin</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>739</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1021/cr030117g</pub-id><?supplied-pmid 15700963?><pub-id pub-id-type="pmid">15700963</pub-id></element-citation></ref><ref id="B16-antibiotics-12-00035"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>C.Y.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Crnovcic</surname><given-names>I.</given-names></name>
<name><surname>Annaval</surname><given-names>T.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Nocek</surname><given-names>B.</given-names></name>
<name><surname>Rudolf</surname><given-names>J.D.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Hindra</surname></name>
<name><surname>Babnigg</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Resistance to enediyne antitumor antibiotics by sequestration</article-title><source>Cell Chem. Biol.</source><year>2018</year><volume>25</volume><fpage>1075</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.05.012</pub-id><pub-id pub-id-type="pmid">29937405</pub-id></element-citation></ref><ref id="B17-antibiotics-12-00035"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>W.H.</given-names></name>
<name><surname>Pu</surname><given-names>J.Y.</given-names></name>
<name><surname>Tang</surname><given-names>M.C.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Peng</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Extracellularly oxidative activation and inactivation of matured prodrug for cryptic self-resistance in naphthyridinomycin biosynthesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>11232</fpage><lpage>11237</lpage><pub-id pub-id-type="doi">10.1073/pnas.1800502115</pub-id><?supplied-pmid 30327344?><pub-id pub-id-type="pmid">30327344</pub-id></element-citation></ref><ref id="B18-antibiotics-12-00035"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>W.H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.Y.</given-names></name>
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Jiang</surname><given-names>C.C.</given-names></name>
<name><surname>Tang</surname><given-names>M.C.</given-names></name>
<name><surname>Pu</surname><given-names>J.Y.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.L.</given-names></name>
<name><surname>Shi</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Reductive inactivation of the hemiaminal pharmacophore for resistance against tetrahydroisoquinoline antibiotics</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7085</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27404-3</pub-id><pub-id pub-id-type="pmid">34873166</pub-id></element-citation></ref><ref id="B19-antibiotics-12-00035"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Self-resistance in the biosynthesis of fungal macrolides involving cycles of extracellular oxidative activation and intracellular reductive inactivation</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>6639</fpage><lpage>6645</lpage><pub-id pub-id-type="doi">10.1002/anie.202015442</pub-id></element-citation></ref><ref id="B20-antibiotics-12-00035"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reimer</surname><given-names>D.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>A natural prodrug activation mechanism in the biosynthesis of nonribosomal peptides</article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1039/C3NP70081J</pub-id><?supplied-pmid 24356302?><pub-id pub-id-type="pmid">24356302</pub-id></element-citation></ref><ref id="B21-antibiotics-12-00035"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Chi</surname><given-names>H.T.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Deng</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Two cryptic self-resistance mechanisms in <italic toggle="yes">Streptomyces tenebrarius</italic> reveal insights into the biosynthesis of apramycin</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>8990</fpage><lpage>8996</lpage><pub-id pub-id-type="doi">10.1002/anie.202100687</pub-id></element-citation></ref><ref id="B22-antibiotics-12-00035"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>J.D.</given-names></name>
<name><surname>Williams</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics</article-title><source>Chem. Rev.</source><year>2002</year><volume>102</volume><fpage>1669</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1021/cr010212u</pub-id><?supplied-pmid 11996547?><pub-id pub-id-type="pmid">11996547</pub-id></element-citation></ref><ref id="B23-antibiotics-12-00035"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
<name><surname>Tang</surname><given-names>M.-C.</given-names></name>
<name><surname>Song</surname><given-names>L.-Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Biosynthesis of tetrahydroisoquinoline antibiotics</article-title><source>Curr. Top. Med. Chem.</source><year>2016</year><volume>16</volume><fpage>1717</fpage><lpage>1726</lpage><pub-id pub-id-type="doi">10.2174/1568026616666151012112329</pub-id><pub-id pub-id-type="pmid">26456466</pub-id></element-citation></ref><ref id="B24-antibiotics-12-00035"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
</person-group><article-title>Compartmentalized biosynthesis of fungal natural products</article-title><source>Curr. Opin. Biotechnol.</source><year>2021</year><volume>69</volume><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2020.12.006</pub-id><pub-id pub-id-type="pmid">33450704</pub-id></element-citation></ref><ref id="B25-antibiotics-12-00035"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Qu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Qi</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Men</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Compartmentalized biosynthesis of mycophenolic acid</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>13305</fpage><lpage>13310</lpage><pub-id pub-id-type="doi">10.1073/pnas.1821932116</pub-id><?supplied-pmid 31209052?><pub-id pub-id-type="pmid">31209052</pub-id></element-citation></ref><ref id="B26-antibiotics-12-00035"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stierle</surname><given-names>A.A.</given-names></name>
<name><surname>Stierle</surname><given-names>D.B.</given-names></name>
<name><surname>Decato</surname><given-names>D.</given-names></name>
<name><surname>Priestley</surname><given-names>N.D.</given-names></name>
<name><surname>Alverson</surname><given-names>J.B.</given-names></name>
<name><surname>Hoody</surname><given-names>J.</given-names></name>
<name><surname>McGrath</surname><given-names>K.</given-names></name>
<name><surname>Klepacki</surname><given-names>D.</given-names></name>
</person-group><article-title>The berkeleylactones, antibiotic macrolides from fungal coculture</article-title><source>J. Nat. Prod.</source><year>2017</year><volume>80</volume><fpage>1150</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.7b00133</pub-id><?supplied-pmid 28326781?><pub-id pub-id-type="pmid">28326781</pub-id></element-citation></ref><ref id="B27-antibiotics-12-00035"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>G.</given-names></name>
<name><surname>Mitova</surname><given-names>M.I.</given-names></name>
<name><surname>Ellis</surname><given-names>G.</given-names></name>
<name><surname>van der Sar</surname><given-names>S.</given-names></name>
<name><surname>Phipps</surname><given-names>R.K.</given-names></name>
<name><surname>Blunt</surname><given-names>J.W.</given-names></name>
<name><surname>Cummings</surname><given-names>N.J.</given-names></name>
<name><surname>Cole</surname><given-names>A.L.J.</given-names></name>
<name><surname>Munro</surname><given-names>M.H.G.</given-names></name>
</person-group><article-title>Bioactivity profiling using HPLC/microtiter-plate analysis:&#x02009; application to a new zealand marine alga-derived fungus, <italic toggle="yes">Gliocladium</italic> sp.</article-title><source>J. Nat. Prod.</source><year>2006</year><volume>69</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1021/np0504917</pub-id><?supplied-pmid 16643039?><pub-id pub-id-type="pmid">16643039</pub-id></element-citation></ref><ref id="B28-antibiotics-12-00035"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canova</surname><given-names>S.</given-names></name>
<name><surname>L&#x000e9;pine</surname><given-names>R.</given-names></name>
<name><surname>Thys</surname><given-names>A.</given-names></name>
<name><surname>Baron</surname><given-names>A.</given-names></name>
<name><surname>Roche</surname><given-names>D.</given-names></name>
</person-group><article-title>Synthesis and biological properties of macrolactam analogs of the natural product macrolide (&#x02212;)-A26771B</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>4768</fpage><lpage>4772</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.06.073</pub-id><pub-id pub-id-type="pmid">21767951</pub-id></element-citation></ref><ref id="B29-antibiotics-12-00035"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Igarashi</surname><given-names>Y.</given-names></name>
<name><surname>Futamata</surname><given-names>K.</given-names></name>
<name><surname>Fujita</surname><given-names>T.</given-names></name>
<name><surname>Sekine</surname><given-names>A.</given-names></name>
<name><surname>Furumai</surname><given-names>T.</given-names></name>
</person-group><article-title>Yatakemycin, a novel antifungal antibiotic produced by <italic toggle="yes">Streptomyces</italic> sp. TP-A0356</article-title><source>J. Antibiot.</source><year>2003</year><volume>56</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.56.107</pub-id></element-citation></ref><ref id="B30-antibiotics-12-00035"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parrish</surname><given-names>J.P.</given-names></name>
<name><surname>Kastrinsky</surname><given-names>D.B.</given-names></name>
<name><surname>Wolkenberg</surname><given-names>S.E.</given-names></name>
<name><surname>Igarashi</surname><given-names>Y.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>DNA alkylation properties of yatakemycin</article-title><source>J. Am. Chem. Soc.</source><year>2003</year><volume>125</volume><fpage>10971</fpage><lpage>10976</lpage><pub-id pub-id-type="doi">10.1021/ja035984h</pub-id><pub-id pub-id-type="pmid">12952479</pub-id></element-citation></ref><ref id="B31-antibiotics-12-00035"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>W.</given-names></name>
<name><surname>Trzupek</surname><given-names>J.D.</given-names></name>
<name><surname>Rayl</surname><given-names>T.J.</given-names></name>
<name><surname>Broward</surname><given-names>M.A.</given-names></name>
<name><surname>Vielhauer</surname><given-names>G.A.</given-names></name>
<name><surname>Weir</surname><given-names>S.J.</given-names></name>
<name><surname>Hwang</surname><given-names>I.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>A unique class of duocarmycin and CC-1065 analogues subject to reductive activation</article-title><source>J. Am. Chem. Soc.</source><year>2007</year><volume>129</volume><fpage>15391</fpage><lpage>15397</lpage><pub-id pub-id-type="doi">10.1021/ja075398e</pub-id><pub-id pub-id-type="pmid">18020335</pub-id></element-citation></ref><ref id="B32-antibiotics-12-00035"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MacMillan</surname><given-names>K.S.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065</article-title><source>J. Med. Chem.</source><year>2009</year><volume>52</volume><fpage>5771</fpage><lpage>5780</lpage><pub-id pub-id-type="doi">10.1021/jm9006214</pub-id><?supplied-pmid 19639994?><pub-id pub-id-type="pmid">19639994</pub-id></element-citation></ref><ref id="B33-antibiotics-12-00035"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>E.A.</given-names></name>
<name><surname>Shi</surname><given-names>R.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Toxicity and repair of DNA adducts produced by the natural product yatakemycin</article-title><source>Nat. Chem. Biol.</source><year>2017</year><volume>13</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2439</pub-id><?supplied-pmid 28759018?><pub-id pub-id-type="pmid">28759018</pub-id></element-citation></ref><ref id="B34-antibiotics-12-00035"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Jakobi</surname><given-names>K.</given-names></name>
<name><surname>Welzel</surname><given-names>K.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyketide</article-title><source>Chem. Biol.</source><year>2005</year><volume>12</volume><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2005.04.017</pub-id><?supplied-pmid 15911378?><pub-id pub-id-type="pmid">15911378</pub-id></element-citation></ref><ref id="B35-antibiotics-12-00035"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Chan</surname><given-names>H.C.S.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Jin</surname><given-names>W.-B.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>GyrI-like proteins catalyze cyclopropanoid hydrolysis to confer cellular protection</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1485</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01508-1</pub-id><pub-id pub-id-type="pmid">29133784</pub-id></element-citation></ref><ref id="B36-antibiotics-12-00035"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>Q.-L.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.-X.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
</person-group><article-title>Self-resistance to an antitumor antibiotic: A DNA glycosylase triggers the base-excision repair system in yatakemycin biosynthesis</article-title><source>Angew. Chem. Int. Ed.</source><year>2012</year><volume>51</volume><fpage>10532</fpage><lpage>10536</lpage><pub-id pub-id-type="doi">10.1002/anie.201204109</pub-id></element-citation></ref><ref id="B37-antibiotics-12-00035"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>E.A.</given-names></name>
<name><surname>Dorival</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Structural evolution of a DNA repair self-resistance mechanism targeting genotoxic secondary metabolites</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>6942</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27284-7</pub-id><pub-id pub-id-type="pmid">34836957</pub-id></element-citation></ref><ref id="B38-antibiotics-12-00035"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>E.A.</given-names></name>
<name><surname>Shi</surname><given-names>R.</given-names></name>
<name><surname>Parsons</surname><given-names>Z.D.</given-names></name>
<name><surname>Yuen</surname><given-names>P.K.</given-names></name>
<name><surname>David</surname><given-names>S.S.</given-names></name>
<name><surname>Igarashi</surname><given-names>Y.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
</person-group><article-title>The DNA glycosylase AlkD uses a non-base-flipping mechanism to excise bulky lesions</article-title><source>Nature</source><year>2015</year><volume>527</volume><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/nature15728</pub-id><pub-id pub-id-type="pmid">26524531</pub-id></element-citation></ref><ref id="B39-antibiotics-12-00035"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sch&#x000e4;rer</surname><given-names>O.D.</given-names></name>
</person-group><article-title>Chemistry and biology of DNA repair</article-title><source>Angew. Chem. Int. Ed.</source><year>2003</year><volume>42</volume><fpage>2946</fpage><lpage>2974</lpage><pub-id pub-id-type="doi">10.1002/anie.200200523</pub-id></element-citation></ref><ref id="B40-antibiotics-12-00035"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stivers</surname><given-names>J.T.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.L.</given-names></name>
</person-group><article-title>A mechanistic perspective on the chemistry of DNA repair glycosylases</article-title><source>Chem. Rev.</source><year>2003</year><volume>103</volume><fpage>2729</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1021/cr010219b</pub-id><pub-id pub-id-type="pmid">12848584</pub-id></element-citation></ref><ref id="B41-antibiotics-12-00035"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.S.</given-names></name>
<name><surname>Perez</surname><given-names>R.J.</given-names></name>
<name><surname>Burk</surname><given-names>C.H.</given-names></name>
<name><surname>Navarro</surname><given-names>A.</given-names></name>
</person-group><article-title>Studies on the mechanism of action of azinomycin B:&#x02009; definition of regioselectivity and sequence selectivity of DNA cross-link formation and clarification of the role of the naphthoate</article-title><source>J. Am. Chem. Soc.</source><year>2002</year><volume>124</volume><fpage>13008</fpage><lpage>13017</lpage><pub-id pub-id-type="doi">10.1021/ja025563k</pub-id><pub-id pub-id-type="pmid">12405827</pub-id></element-citation></ref><ref id="B42-antibiotics-12-00035"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foulke-Abel</surname><given-names>J.</given-names></name>
<name><surname>Kelly</surname><given-names>G.T.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Watanabe</surname><given-names>C.</given-names></name>
</person-group><article-title>Characterization of AziR, a resistance protein of the DNA cross-linking agent azinomycin B</article-title><source>Mol. Biosyst.</source><year>2011</year><volume>7</volume><fpage>2563</fpage><lpage>2570</lpage><pub-id pub-id-type="doi">10.1039/c1mb05136a</pub-id><pub-id pub-id-type="pmid">21776524</pub-id></element-citation></ref><ref id="B43-antibiotics-12-00035"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Lei</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Feng</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Characterization of a novel DNA glycosylase from <italic toggle="yes">S. sahachiroi</italic> involved in the reduction and repair of azinomycin B induced DNA damage</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv949</pub-id><?supplied-pmid 26400161?><pub-id pub-id-type="pmid">26400161</pub-id></element-citation></ref><ref id="B44-antibiotics-12-00035"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>E.A.</given-names></name>
<name><surname>Warren</surname><given-names>G.M.</given-names></name>
<name><surname>Bradley</surname><given-names>N.P.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Structure of a DNA glycosylase that unhooks interstrand cross-links</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>4400</fpage><lpage>4405</lpage><pub-id pub-id-type="doi">10.1073/pnas.1703066114</pub-id><?supplied-pmid 28396405?><pub-id pub-id-type="pmid">28396405</pub-id></element-citation></ref><ref id="B45-antibiotics-12-00035"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Ying</surname><given-names>K.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Zuo</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
</person-group><article-title>Identification of a novel structure-specific endonuclease AziN that contributes to the repair of azinomycin B-mediated DNA interstrand crosslinks</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>709</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1067</pub-id><?supplied-pmid 31713613?><pub-id pub-id-type="pmid">31713613</pub-id></element-citation></ref><ref id="B46-antibiotics-12-00035"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maskey</surname><given-names>R.P.</given-names></name>
<name><surname>Helmke</surname><given-names>E.</given-names></name>
<name><surname>Kayser</surname><given-names>O.</given-names></name>
<name><surname>Fiebig</surname><given-names>H.H.</given-names></name>
<name><surname>Maier</surname><given-names>A.</given-names></name>
<name><surname>Busche</surname><given-names>A.</given-names></name>
<name><surname>Laatsch</surname><given-names>H.</given-names></name>
</person-group><article-title>Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine <italic toggle="yes">Streptomycete</italic> and their absolute stereochemistry</article-title><source>J. Antibiot.</source><year>2004</year><volume>57</volume><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.57.771</pub-id></element-citation></ref><ref id="B47-antibiotics-12-00035"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maiese</surname><given-names>W.M.</given-names></name>
<name><surname>Labeda</surname><given-names>D.P.</given-names></name>
<name><surname>Korshalla</surname><given-names>J.</given-names></name>
<name><surname>Kuck</surname><given-names>N.</given-names></name>
<name><surname>Fantini</surname><given-names>A.A.</given-names></name>
<name><surname>Wildey</surname><given-names>M.J.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Greenstein</surname><given-names>M.</given-names></name>
</person-group><article-title>LL-D49194 antibiotics, a novel family of antitumor agents: Taxonomy, fermentation and biological properties</article-title><source>J. Antibiot.</source><year>2006</year><volume>43</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.43.253</pub-id></element-citation></ref><ref id="B48-antibiotics-12-00035"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitzner</surname><given-names>A.</given-names></name>
<name><surname>Frauendorf</surname><given-names>H.</given-names></name>
<name><surname>Laatsch</surname><given-names>H.</given-names></name>
<name><surname>Diederichsen</surname><given-names>U.</given-names></name>
</person-group><article-title>Formation of gutingimycin: Analytical investigation of trioxacarcin A-mediated alkylation of dsDNA</article-title><source>Anal. Bioanal. Chem.</source><year>2008</year><volume>390</volume><fpage>1139</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1007/s00216-007-1737-6</pub-id><?supplied-pmid 18210096?><pub-id pub-id-type="pmid">18210096</pub-id></element-citation></ref><ref id="B49-antibiotics-12-00035"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pfoh</surname><given-names>R.</given-names></name>
<name><surname>Laatsch</surname><given-names>H.</given-names></name>
<name><surname>Sheldrick</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Crystal structure of trioxacarcin A covalently bound to DNA</article-title><source>Nucleic Acids Res.</source><year>2008</year><volume>36</volume><fpage>3508</fpage><lpage>3514</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn245</pub-id><pub-id pub-id-type="pmid">18453630</pub-id></element-citation></ref><ref id="B50-antibiotics-12-00035"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>E.A.</given-names></name>
<name><surname>Rubinson</surname><given-names>E.H.</given-names></name>
<name><surname>Pereira</surname><given-names>K.N.</given-names></name>
<name><surname>Calcutt</surname><given-names>M.W.</given-names></name>
<name><surname>Christov</surname><given-names>P.P.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
</person-group><article-title>An HPLC&#x02013;tandem mass spectrometry method for simultaneous detection of alkylated base excision repair products</article-title><source>Methods.</source><year>2013</year><volume>64</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2013.07.020</pub-id><pub-id pub-id-type="pmid">23876937</pub-id></element-citation></ref><ref id="B51-antibiotics-12-00035"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Hou</surname><given-names>X.-F.</given-names></name>
<name><surname>Qi</surname><given-names>L.-H.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Pan</surname><given-names>H.-X.</given-names></name>
<name><surname>Chen</surname><given-names>X.-Y.</given-names></name>
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
</person-group><article-title>Biosynthesis of trioxacarcin revealing a different starter unit and complex tailoring steps for type II polyketide synthase</article-title><source>Chem. Sci.</source><year>2015</year><volume>6</volume><fpage>3440</fpage><lpage>3447</lpage><pub-id pub-id-type="doi">10.1039/C5SC00116A</pub-id><pub-id pub-id-type="pmid">29511509</pub-id></element-citation></ref><ref id="B52-antibiotics-12-00035"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Qi</surname><given-names>L.-H.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Hou</surname><given-names>X.-F.</given-names></name>
<name><surname>Pan</surname><given-names>H.-X.</given-names></name>
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
</person-group><article-title>The SARP family regulator Txn9 and two-component response regulator Txn11 are key activators for trioxacarcin biosynthesis in <italic toggle="yes">Streptomyces bottropensis</italic></article-title><source>Curr. Microbiol.</source><year>2015</year><volume>71</volume><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00284-015-0868-9</pub-id><?supplied-pmid 26178900?><pub-id pub-id-type="pmid">26178900</pub-id></element-citation></ref><ref id="B53-antibiotics-12-00035"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Hou</surname><given-names>X.F.</given-names></name>
<name><surname>Li</surname><given-names>W.J.</given-names></name>
<name><surname>Tang</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Discovery of druggability-improved analogues by investigation of the LL-D49194alpha1 biosynthetic pathway</article-title><source>Org. Lett.</source><year>2019</year><volume>21</volume><fpage>2322</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.9b00610</pub-id><pub-id pub-id-type="pmid">30855966</pub-id></element-citation></ref><ref id="B54-antibiotics-12-00035"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Bradley</surname><given-names>N.P.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Wahl</surname><given-names>K.L.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Hou</surname><given-names>X.F.</given-names></name>
<name><surname>Eichman</surname><given-names>B.F.</given-names></name>
<name><surname>Tang</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Base excision repair system targeting DNA adducts of trioxacarcin/LL-D49194 antibiotics for self-resistance</article-title><source>Nucleic Acids Res.</source><year>2022</year><volume>50</volume><fpage>2417</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac085</pub-id><?supplied-pmid 35191495?><pub-id pub-id-type="pmid">35191495</pub-id></element-citation></ref><ref id="B55-antibiotics-12-00035"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heifets</surname><given-names>L.</given-names></name>
<name><surname>Simon J Fau-Pham</surname><given-names>V.</given-names></name>
<name><surname>Pham</surname><given-names>V.</given-names></name>
</person-group><article-title>Capreomycin is active against non-replicating <italic toggle="yes">M. tuberculosis</italic></article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2005</year><volume>4</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-4-6</pub-id><pub-id pub-id-type="pmid">15804353</pub-id></element-citation></ref><ref id="B56-antibiotics-12-00035"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>R.</given-names></name>
<name><surname>Itagaki N Fau-Sugawara</surname><given-names>I.</given-names></name>
<name><surname>Sugawara</surname><given-names>I.</given-names></name>
</person-group><article-title>Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms</article-title><source>Mini-Rev. Med. Chem.</source><year>2007</year><volume>7</volume><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.2174/138955707782331740</pub-id><?supplied-pmid 18045221?><pub-id pub-id-type="pmid">18045221</pub-id></element-citation></ref><ref id="B57-antibiotics-12-00035"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stanley</surname><given-names>R.E.</given-names></name>
<name><surname>Blaha</surname><given-names>G.</given-names></name>
<name><surname>Grodzicki</surname><given-names>R.L.</given-names></name>
<name><surname>Strickler</surname><given-names>M.D.</given-names></name>
<name><surname>Steitz</surname><given-names>T.A.</given-names></name>
</person-group><article-title>The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome</article-title><source>Nat. Struct. Mol. Biol.</source><year>2010</year><volume>17</volume><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1755</pub-id><pub-id pub-id-type="pmid">20154709</pub-id></element-citation></ref><ref id="B58-antibiotics-12-00035"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Felnagle</surname><given-names>E.A.</given-names></name>
<name><surname>Rondon</surname><given-names>M.R.</given-names></name>
<name><surname>Berti</surname><given-names>A.D.</given-names></name>
<name><surname>Crosby</surname><given-names>H.A.</given-names></name>
<name><surname>Thomas</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Identification of the biosynthetic gene cluster and an additional gene for resistance to the antituberculosis drug capreomycin</article-title><source>Appl. Environ. Microbiol.</source><year>2007</year><volume>73</volume><fpage>4162</fpage><lpage>4170</lpage><pub-id pub-id-type="doi">10.1128/AEM.00485-07</pub-id><pub-id pub-id-type="pmid">17496129</pub-id></element-citation></ref><ref id="B59-antibiotics-12-00035"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>Y.C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.L.</given-names></name>
<name><surname>Toh</surname><given-names>S.I.</given-names></name>
<name><surname>Hsu</surname><given-names>N.S.</given-names></name>
<name><surname>Lin</surname><given-names>K.H.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>S.C.</given-names></name>
<name><surname>Wu</surname><given-names>T.K.</given-names></name>
<name><surname>Li</surname><given-names>T.L.</given-names></name>
<name><surname>Chang</surname><given-names>C.Y.</given-names></name>
</person-group><article-title>Dual-mechanism confers self-resistance to the antituberculosis antibiotic capreomycin</article-title><source>ACS Chem. Biol.</source><year>2022</year><volume>17</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1021/acschembio.1c00799</pub-id><pub-id pub-id-type="pmid">34994196</pub-id></element-citation></ref><ref id="B60-antibiotics-12-00035"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name>
<name><surname>Homburg</surname><given-names>S.</given-names></name>
<name><surname>Taieb</surname><given-names>F.</given-names></name>
<name><surname>Boury</surname><given-names>M.</given-names></name>
<name><surname>Brzuszkiewicz</surname><given-names>E.</given-names></name>
<name><surname>Gottschalk</surname><given-names>G.</given-names></name>
<name><surname>Buchrieser</surname><given-names>C.</given-names></name>
<name><surname>Hacker</surname><given-names>J.</given-names></name>
<name><surname>Dobrindt</surname><given-names>U.</given-names></name>
<name><surname>Oswald</surname><given-names>E.</given-names></name>
</person-group><article-title><italic toggle="yes">Escherichia coli</italic> induces DNA double-strand breaks in eukaryotic cells</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>848</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1126/science.1127059</pub-id><pub-id pub-id-type="pmid">16902142</pub-id></element-citation></ref><ref id="B61-antibiotics-12-00035"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bondarev</surname><given-names>V.</given-names></name>
<name><surname>Richter</surname><given-names>M.</given-names></name>
<name><surname>Romano</surname><given-names>S.</given-names></name>
<name><surname>Piel</surname><given-names>J.</given-names></name>
<name><surname>Schwedt</surname><given-names>A.</given-names></name>
<name><surname>Schulz-Vogt</surname><given-names>H.N.</given-names></name>
</person-group><article-title>The genus <italic toggle="yes">Pseudovibrio</italic> contains metabolically versatile bacteria adapted for symbiosis</article-title><source>Environ. Microbiol.</source><year>2013</year><volume>15</volume><fpage>2095</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.12123</pub-id><?supplied-pmid 23601235?><pub-id pub-id-type="pmid">23601235</pub-id></element-citation></ref><ref id="B62-antibiotics-12-00035"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Engel</surname><given-names>P.</given-names></name>
<name><surname>Vizcaino Maria</surname><given-names>I.</given-names></name>
<name><surname>Crawford Jason</surname><given-names>M.</given-names></name>
<name><surname>Drake</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Gut symbionts from distinct hosts exhibit genotoxic activity via divergent colibactin biosynthesis pathways</article-title><source>Appl. Environ. Microbiol.</source><year>2015</year><volume>81</volume><fpage>1502</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1128/AEM.03283-14</pub-id><?supplied-pmid 25527542?><pub-id pub-id-type="pmid">25527542</pub-id></element-citation></ref><ref id="B63-antibiotics-12-00035"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Stornetta</surname><given-names>A.</given-names></name>
<name><surname>Villalta</surname><given-names>P.W.</given-names></name>
<name><surname>Wilson</surname><given-names>M.R.</given-names></name>
<name><surname>Boudreau</surname><given-names>P.D.</given-names></name>
<name><surname>Zha</surname><given-names>L.</given-names></name>
<name><surname>Balbo</surname><given-names>S.</given-names></name>
<name><surname>Balskus</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Reactivity of an unusual amidase may explain colibactin&#x02019;s DNA cross-linking activity</article-title><source>J. Am. Chem. Soc.</source><year>2019</year><volume>141</volume><fpage>11489</fpage><lpage>11496</lpage><pub-id pub-id-type="doi">10.1021/jacs.9b02453</pub-id><?supplied-pmid 31251062?><pub-id pub-id-type="pmid">31251062</pub-id></element-citation></ref><ref id="B64-antibiotics-12-00035"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>C.S.</given-names></name>
<name><surname>Healy</surname><given-names>A.R.</given-names></name>
<name><surname>Wernke</surname><given-names>K.M.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Frischling</surname><given-names>M.C.</given-names></name>
<name><surname>Shine</surname><given-names>E.E.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Herzon</surname><given-names>S.B.</given-names></name>
<name><surname>Crawford</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Structure elucidation of colibactin and its DNA cross-links</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>eaax2685</fpage><pub-id pub-id-type="doi">10.1126/science.aax2685</pub-id><?supplied-pmid 31395743?><pub-id pub-id-type="pmid">31395743</pub-id></element-citation></ref><ref id="B65-antibiotics-12-00035"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>J.W.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ye</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Z.R.</given-names></name>
<name><surname>Qian</surname><given-names>P.Y.</given-names></name>
</person-group><article-title>Biosynthesis and bioactivities of microbial genotoxin colibactins</article-title><source>Nat. Prod. Rep.</source><year>2022</year><volume>39</volume><fpage>991</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1039/D1NP00050K</pub-id><pub-id pub-id-type="pmid">35288725</pub-id></element-citation></ref><ref id="B66-antibiotics-12-00035"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bian</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>J.</given-names></name>
<name><surname>Plaza</surname><given-names>A.</given-names></name>
<name><surname>Herrmann</surname><given-names>J.</given-names></name>
<name><surname>Pistorius</surname><given-names>D.</given-names></name>
<name><surname>Stewart</surname><given-names>A.F.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
</person-group><article-title>In vivo evidence for a prodrug activation mechanism during colibactin maturation</article-title><source>ChemBioChem</source><year>2013</year><volume>14</volume><fpage>1194</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300208</pub-id><pub-id pub-id-type="pmid">23744512</pub-id></element-citation></ref><ref id="B67-antibiotics-12-00035"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brotherton</surname><given-names>C.A.</given-names></name>
<name><surname>Balskus</surname><given-names>E.P.</given-names></name>
</person-group><article-title>A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>3359</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1021/ja312154m</pub-id><pub-id pub-id-type="pmid">23406518</pub-id></element-citation></ref><ref id="B68-antibiotics-12-00035"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mousa</surname><given-names>J.J.</given-names></name>
<name><surname>Newsome</surname><given-names>R.C.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Jobin</surname><given-names>C.</given-names></name>
<name><surname>Bruner</surname><given-names>S.D.</given-names></name>
</person-group><article-title>ClbM is a versatile, cation-promiscuous MATE transporter found in the colibactin biosynthetic gene cluster</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>482</volume><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.12.018</pub-id><pub-id pub-id-type="pmid">27939886</pub-id></element-citation></ref><ref id="B69-antibiotics-12-00035"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krah</surname><given-names>A.</given-names></name>
<name><surname>Huber</surname><given-names>R.G.</given-names></name>
<name><surname>Zachariae</surname><given-names>U.</given-names></name>
<name><surname>Bond</surname><given-names>P.J.</given-names></name>
</person-group><article-title>On the ion coupling mechanism of the MATE transporter ClbM</article-title><source>BBA Biomembr.</source><year>2020</year><volume>1862</volume><fpage>183137</fpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2019.183137</pub-id></element-citation></ref><ref id="B70-antibiotics-12-00035"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mousa</surname><given-names>J.J.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Tomkovich</surname><given-names>S.</given-names></name>
<name><surname>Shima</surname><given-names>A.</given-names></name>
<name><surname>Newsome</surname><given-names>R.C.</given-names></name>
<name><surname>Tripathi</surname><given-names>P.</given-names></name>
<name><surname>Oswald</surname><given-names>E.</given-names></name>
<name><surname>Bruner</surname><given-names>S.D.</given-names></name>
<name><surname>Jobin</surname><given-names>C.</given-names></name>
</person-group><article-title>MATE transport of the <italic toggle="yes">E. coli</italic>-derived genotoxin colibactin</article-title><source>Nat. Microbiol.</source><year>2016</year><volume>1</volume><fpage>15009</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2015.9</pub-id><pub-id pub-id-type="pmid">27571755</pub-id></element-citation></ref><ref id="B71-antibiotics-12-00035"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velilla</surname><given-names>J.A.</given-names></name>
<name><surname>Volpe</surname><given-names>M.R.</given-names></name>
<name><surname>Kenney</surname><given-names>G.E.</given-names></name>
<name><surname>Walsh</surname><given-names>R.M.</given-names><suffix>Jr.</suffix></name>
<name><surname>Balskus</surname><given-names>E.P.</given-names></name>
<name><surname>Gaudet</surname><given-names>R.</given-names></name>
</person-group><article-title>Structural basis of colibactin activation by the ClbP peptidase</article-title><source>Nat. Chem. Biol.</source><year>2022</year><pub-id pub-id-type="doi">10.1038/s41589-022-01142-z</pub-id></element-citation></ref><ref id="B72-antibiotics-12-00035"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tripathi</surname><given-names>P.</given-names></name>
<name><surname>Shine</surname><given-names>E.E.</given-names></name>
<name><surname>Healy</surname><given-names>A.R.</given-names></name>
<name><surname>Kim</surname><given-names>C.S.</given-names></name>
<name><surname>Herzon</surname><given-names>S.B.</given-names></name>
<name><surname>Bruner</surname><given-names>S.D.</given-names></name>
<name><surname>Crawford</surname><given-names>J.M.</given-names></name>
</person-group><article-title>ClbS Is a cyclopropane hydrolase that confers colibactin resistance</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>17719</fpage><lpage>17722</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b09971</pub-id><?supplied-pmid 29112397?><pub-id pub-id-type="pmid">29112397</pub-id></element-citation></ref><ref id="B73-antibiotics-12-00035"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tripathi</surname><given-names>P.</given-names></name>
<name><surname>Bruner</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Structural basis for the interactions of the colibactin resistance gene product ClbS with DNA</article-title><source>Biochemistry</source><year>2021</year><volume>60</volume><fpage>1619</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.1c00201</pub-id><?supplied-pmid 33945270?><pub-id pub-id-type="pmid">33945270</pub-id></element-citation></ref><ref id="B74-antibiotics-12-00035"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Molan</surname><given-names>K.</given-names></name>
<name><surname>Podlesek</surname><given-names>Z.</given-names></name>
<name><surname>Hodnik</surname><given-names>V.</given-names></name>
<name><surname>Butala</surname><given-names>M.</given-names></name>
<name><surname>Oswald</surname><given-names>E.</given-names></name>
<name><surname>&#x0017d;gur Bertok</surname><given-names>D.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Escherichia coli</italic> colibactin resistance protein ClbS is a novel DNA binding protein that protects DNA from nucleolytic degradation</article-title><source>DNA Repair.</source><year>2019</year><volume>79</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2019.05.003</pub-id><?supplied-pmid 31129429?><pub-id pub-id-type="pmid">31129429</pub-id></element-citation></ref><ref id="B75-antibiotics-12-00035"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Ellabaan</surname><given-names>M.M.H.</given-names></name>
<name><surname>Charusanti</surname><given-names>P.</given-names></name>
<name><surname>Munck</surname><given-names>C.</given-names></name>
<name><surname>Blin</surname><given-names>K.</given-names></name>
<name><surname>Tong</surname><given-names>Y.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
<name><surname>Sommer</surname><given-names>M.O.A.</given-names></name>
<name><surname>Lee</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>Dissemination of antibiotic resistance genes from antibiotic producers to pathogens</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15784</fpage><pub-id pub-id-type="doi">10.1038/ncomms15784</pub-id><pub-id pub-id-type="pmid">28589945</pub-id></element-citation></ref><ref id="B76-antibiotics-12-00035"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sikandar</surname><given-names>A.</given-names></name>
<name><surname>Cirnski</surname><given-names>K.</given-names></name>
<name><surname>Testolin</surname><given-names>G.</given-names></name>
<name><surname>Volz</surname><given-names>C.</given-names></name>
<name><surname>Bronstrup</surname><given-names>M.</given-names></name>
<name><surname>Kalinina</surname><given-names>O.V.</given-names></name>
<name><surname>Muller</surname><given-names>R.</given-names></name>
<name><surname>Koehnke</surname><given-names>J.</given-names></name>
</person-group><article-title>Adaptation of a bacterial multidrug resistance system revealed by the structure and function of AlbA</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>16641</fpage><lpage>16649</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b08895</pub-id><pub-id pub-id-type="pmid">30422653</pub-id></element-citation></ref><ref id="B77-antibiotics-12-00035"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rostock</surname><given-names>L.</given-names></name>
<name><surname>Driller</surname><given-names>R.</given-names></name>
<name><surname>Gratz</surname><given-names>S.</given-names></name>
<name><surname>Kerwat</surname><given-names>D.</given-names></name>
<name><surname>von Eckardstein</surname><given-names>L.</given-names></name>
<name><surname>Petras</surname><given-names>D.</given-names></name>
<name><surname>Kunert</surname><given-names>M.</given-names></name>
<name><surname>Alings</surname><given-names>C.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.J.</given-names></name>
<name><surname>Friedrich</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Molecular insights into antibiotic resistance&#x02014;How a binding protein traps albicidin</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3095</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05551-4</pub-id><pub-id pub-id-type="pmid">30082794</pub-id></element-citation></ref><ref id="B78-antibiotics-12-00035"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balaich</surname><given-names>J.</given-names></name>
<name><surname>Estrella</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>G.</given-names></name>
<name><surname>Jeffrey</surname><given-names>P.D.</given-names></name>
<name><surname>Biswas</surname><given-names>A.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Korennykh</surname><given-names>A.</given-names></name>
<name><surname>Donia</surname><given-names>M.S.</given-names></name>
</person-group><article-title>The human microbiome encodes resistance to the antidiabetic drug acarbose</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04091-0</pub-id><pub-id pub-id-type="pmid">34819672</pub-id></element-citation></ref><ref id="B79-antibiotics-12-00035"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wehmeier</surname><given-names>U.F.</given-names></name>
</person-group><article-title>The biosynthesis and metabolism of acarbose in <italic toggle="yes">Actinoplanes</italic> sp. SE 50/110: A progress report</article-title><source>Biocatal. Biotransform.</source><year>2003</year><volume>21</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1080/10242420310001614388</pub-id></element-citation></ref><ref id="B80-antibiotics-12-00035"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harvey</surname><given-names>A.L.</given-names></name>
<name><surname>Edrada-Ebel</surname><given-names>R.</given-names></name>
<name><surname>Quinn</surname><given-names>R.J.</given-names></name>
</person-group><article-title>The re-emergence of natural products for drug discovery in the genomics era</article-title><source>Nat. Rev. Drug. Discov.</source><year>2015</year><volume>14</volume><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nrd4510</pub-id><pub-id pub-id-type="pmid">25614221</pub-id></element-citation></ref><ref id="B81-antibiotics-12-00035"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Lanen</surname><given-names>S.G.</given-names></name>
<name><surname>Shen</surname><given-names>B.</given-names></name>
</person-group><article-title>Microbial genomics for the improvement of natural product discovery</article-title><source>Curr. Opin. Microbiol.</source><year>2006</year><volume>9</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2006.04.002</pub-id><pub-id pub-id-type="pmid">16651020</pub-id></element-citation></ref><ref id="B82-antibiotics-12-00035"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherlach</surname><given-names>K.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Triggering cryptic natural product biosynthesis in microorganisms</article-title><source>Org. Biomol. Chem.</source><year>2009</year><volume>7</volume><fpage>1753</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1039/b821578b</pub-id><?supplied-pmid 19590766?><pub-id pub-id-type="pmid">19590766</pub-id></element-citation></ref><ref id="B83-antibiotics-12-00035"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walsh</surname><given-names>C.T.</given-names></name>
<name><surname>Fischbach</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Natural products version 2.0: Connecting genes to molecules</article-title><source>J. Am. Chem. Soc.</source><year>2010</year><volume>132</volume><fpage>2469</fpage><lpage>2493</lpage><pub-id pub-id-type="doi">10.1021/ja909118a</pub-id><?supplied-pmid 20121095?><pub-id pub-id-type="pmid">20121095</pub-id></element-citation></ref><ref id="B84-antibiotics-12-00035"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thaker</surname><given-names>M.N.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name>
<name><surname>Waglechner</surname><given-names>N.</given-names></name>
<name><surname>King</surname><given-names>A.M.</given-names></name>
<name><surname>Medina</surname><given-names>R.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Identifying producers of antibacterial compounds by screening for antibiotic resistance</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/nbt.2685</pub-id><?supplied-pmid 24056948?><pub-id pub-id-type="pmid">24056948</pub-id></element-citation></ref><ref id="B85-antibiotics-12-00035"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alanjary</surname><given-names>M.</given-names></name>
<name><surname>Kronmiller</surname><given-names>B.</given-names></name>
<name><surname>Adamek</surname><given-names>M.</given-names></name>
<name><surname>Blin</surname><given-names>K.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
<name><surname>Huson</surname><given-names>D.</given-names></name>
<name><surname>Philmus</surname><given-names>B.</given-names></name>
<name><surname>Ziemert</surname><given-names>N.</given-names></name>
</person-group><article-title>The antibiotic resistant target seeker (ARTS), an exploration engine for antibiotic cluster prioritization and novel drug target discovery</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W42</fpage><lpage>W48</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx360</pub-id><pub-id pub-id-type="pmid">28472505</pub-id></element-citation></ref><ref id="B86-antibiotics-12-00035"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panter</surname><given-names>F.</given-names></name>
<name><surname>Krug</surname><given-names>D.</given-names></name>
<name><surname>Baumann</surname><given-names>S.</given-names></name>
<name><surname>Muller</surname><given-names>R.</given-names></name>
</person-group><article-title>Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria</article-title><source>Chem. Sci.</source><year>2018</year><volume>9</volume><fpage>4898</fpage><lpage>4908</lpage><pub-id pub-id-type="doi">10.1039/C8SC01325J</pub-id><pub-id pub-id-type="pmid">29910943</pub-id></element-citation></ref><ref id="B87-antibiotics-12-00035"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Culp</surname><given-names>E.J.</given-names></name>
<name><surname>Sychantha</surname><given-names>D.</given-names></name>
<name><surname>Hobson</surname><given-names>C.</given-names></name>
<name><surname>Pawlowski</surname><given-names>A.C.</given-names></name>
<name><surname>Prehna</surname><given-names>G.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>ClpP inhibitors are produced by a widespread family of bacterial gene clusters</article-title><source>Nat. Microbiol.</source><year>2022</year><volume>7</volume><fpage>451</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01073-4</pub-id><pub-id pub-id-type="pmid">35246663</pub-id></element-citation></ref><ref id="B88-antibiotics-12-00035"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.Y.</given-names></name>
<name><surname>Hu</surname><given-names>Y.L.</given-names></name>
<name><surname>Sun</surname><given-names>J.L.</given-names></name>
<name><surname>Yu</surname><given-names>L.B.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.R.</given-names></name>
<name><surname>Guo</surname><given-names>Z.K.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Tan</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Resistance and phylogeny guided discovery reveals structural novelty of tetracycline antibiotics</article-title><source>Chem. Sci.</source><year>2022</year><volume>13</volume><fpage>12892</fpage><lpage>12898</lpage><pub-id pub-id-type="doi">10.1039/D2SC03965F</pub-id><pub-id pub-id-type="pmid">36519048</pub-id></element-citation></ref><ref id="B89-antibiotics-12-00035"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>T.A.</given-names></name>
<name><surname>Batey</surname><given-names>S.F.D.</given-names></name>
<name><surname>Wiencek</surname><given-names>P.</given-names></name>
<name><surname>Chandra</surname><given-names>G.</given-names></name>
<name><surname>Alt</surname><given-names>S.</given-names></name>
<name><surname>Francklyn</surname><given-names>C.S.</given-names></name>
<name><surname>Wilkinson</surname><given-names>B.</given-names></name>
</person-group><article-title>Immunity-guided identification of threonyl-tRNA synthetase as the molecular target of obafluorin, a beta-lactone antibiotic</article-title><source>ACS Chem. Biol.</source><year>2019</year><volume>14</volume><fpage>2663</fpage><lpage>2671</lpage><pub-id pub-id-type="doi">10.1021/acschembio.9b00590</pub-id><pub-id pub-id-type="pmid">31675206</pub-id></element-citation></ref><ref id="B90-antibiotics-12-00035"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vinale</surname><given-names>F.</given-names></name>
<name><surname>Flematti</surname><given-names>G.</given-names></name>
<name><surname>Sivasithamparam</surname><given-names>K.</given-names></name>
<name><surname>Lorito</surname><given-names>M.</given-names></name>
<name><surname>Marra</surname><given-names>R.</given-names></name>
<name><surname>Skelton</surname><given-names>B.W.</given-names></name>
<name><surname>Ghisalberti</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Harzianic acid, an antifungal and plant growth promoting metabolite from <italic toggle="yes">Trichoderma harzianum</italic></article-title><source>J. Nat. Prod.</source><year>2009</year><volume>72</volume><fpage>2032</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1021/np900548p</pub-id><pub-id pub-id-type="pmid">19894739</pub-id></element-citation></ref><ref id="B91-antibiotics-12-00035"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Zang</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Harzianic acid from trichoderma afroharzianum is a natural product inhibitor of acetohydroxyacid synthase</article-title><source>J. Am. Chem. Soc.</source><year>2021</year><volume>143</volume><fpage>9575</fpage><lpage>9584</lpage><pub-id pub-id-type="doi">10.1021/jacs.1c03988</pub-id></element-citation></ref><ref id="B92-antibiotics-12-00035"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>B.</given-names></name>
<name><surname>Wan</surname><given-names>J.</given-names></name>
<name><surname>Shang</surname><given-names>C.</given-names></name>
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>J.</given-names></name>
<name><surname>Cen</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Biosynthesis of rumbrins and inspiration for discovery of HIV inhibitors</article-title><source>Acta Pharm. Sin. B.</source><year>2022</year><volume>12</volume><fpage>4193</fpage><lpage>4203</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.005</pub-id><?supplied-pmid 36386473?><pub-id pub-id-type="pmid">36386473</pub-id></element-citation></ref><ref id="B93-antibiotics-12-00035"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Culp</surname><given-names>E.J.</given-names></name>
<name><surname>Waglechner</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Fiebig-Comyn</surname><given-names>A.A.</given-names></name>
<name><surname>Hsu</surname><given-names>Y.P.</given-names></name>
<name><surname>Koteva</surname><given-names>K.</given-names></name>
<name><surname>Sychantha</surname><given-names>D.</given-names></name>
<name><surname>Coombes</surname><given-names>B.K.</given-names></name>
<name><surname>Van Nieuwenhze</surname><given-names>M.S.</given-names></name>
<name><surname>Brun</surname><given-names>Y.V.</given-names></name>
<etal/>
</person-group><article-title>Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling</article-title><source>Nature</source><year>2020</year><volume>578</volume><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1990-9</pub-id><?supplied-pmid 32051588?><pub-id pub-id-type="pmid">32051588</pub-id></element-citation></ref><ref id="B94-antibiotics-12-00035"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hobson</surname><given-names>C.</given-names></name>
<name><surname>Chan</surname><given-names>A.N.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>The antibiotic resistome: A guide for the discovery of natural products as antimicrobial agents</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>3464</fpage><lpage>3494</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01214</pub-id><?supplied-pmid 33606500?><pub-id pub-id-type="pmid">33606500</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-12-00035-f001"><label>Figure 1</label><caption><p>Representative natural products that employ temporal-spatial shielding or intracellular multi-level resistance model during biosynthesis.</p></caption><graphic xlink:href="antibiotics-12-00035-g001" position="float"/></fig><fig position="float" id="antibiotics-12-00035-f002"><label>Figure 2</label><caption><p>Examples of temporal-spatial shielding resistance model. (<bold>A</bold>) Self-resistance mechanisms of NDM producer Streptomyces lusitanus. Cytosol-located short-chain dehydrogenase/reductase NapW confers temporal shielding of NDM cytotoxicity by detoxification of biosynthetic intermediate and inactivation of re-entered final product. The membrane protease NapG couples with the secreted oxidoreductase NapU contributes to spatial shielding of NDM activity by prodrug maturation, NDM activation and inactivation. (<bold>B</bold>) Self-resistance mechanisms of A26771B producer Penicillium turbatum. Activation of the final product A26771B in extracellular space by the secreted oxidoreductase BerkD ensures the safety of producer via spatial shielding. Intracellular A26771B inactivation by cytoplasmic short-chain reductase BerkC and the subsequent recycling of the products control the self-harm of its producer from time.</p></caption><graphic xlink:href="antibiotics-12-00035-g002" position="float"/></fig><fig position="float" id="antibiotics-12-00035-f003"><label>Figure 3</label><caption><p>Examples of intracellular multi-level resistance model. (<bold>A</bold>) Self-resistance strategies employed by yatakemycin (YTM) producing strain <italic toggle="yes">Streptomyces</italic> sp. TP-3056. The producer is known to be protected by seven resistance genes that function in efflux pumps, chemical modification and damage repair. (<bold>B</bold>) Self-protection mechanisms of azinomycin B (AZB) producing strain Streptomyces sahachiroi. The drug-bind protein AziR, transmembrane export protein AziE, DNA damage repair enzymes AlkZ and AziN confer resistance to AZB in <italic toggle="yes">Streptomyces sahachiroi</italic> via drug sequestration, efflux pumps, target protection and damage repair, respectively. (<bold>C</bold>) Self-resistance strategies employed by trioxacarcin A (TXNA) producer <italic toggle="yes">Streptomyces bottropensis</italic>. To withstand the genotoxicity of TXN, the producer has evolved drug efflux pump and DNA damage repair mechanisms. (<bold>D</bold>) Multi-level resistance mechanism in capreomycin (CMN)-producing strain <italic toggle="yes">Saccharothrix mutabilis</italic> subsp. <italic toggle="yes">capreolus</italic>. N-acetyltransferase Cac is responsible for inactivating CMN IIA and IIB via acetylation, methyltransferase CmnU confers resistance to CMN by methylating 16S rRNA, phosphotransferase Cph plays role in the phosphorylation of CMN IA and IIA, and it also serves as an antibiotic sequester to inactivate CMN IIB by physical sequestration. (<bold>E</bold>) Multi-level resistance mechanism in colibactin-770-producing strain <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">pks+</italic>). Nonribosomal peptide synthetases ClbN and ClbB prevent the formation of the active imine moiety during early stage of colibactin biosynthesis, inner-membrane transporter ClbM and peptidase ClbP are responsible for prodrug maturation and efflux. Moreover, the intracellular cyclopropane hydrolase ClbS abrogates cytotoxicity of the offloaded intermediates or re-entered colibactin.</p></caption><graphic xlink:href="antibiotics-12-00035-g003" position="float"/></fig><fig position="float" id="antibiotics-12-00035-f004"><label>Figure 4</label><caption><p>Representative natural products that resistance determinants are widespread in nature.</p></caption><graphic xlink:href="antibiotics-12-00035-g004" position="float"/></fig><fig position="float" id="antibiotics-12-00035-f005"><label>Figure 5</label><caption><p>Structures of representative natural products that discovered by using antibiotic resistance gene as a probe.</p></caption><graphic xlink:href="antibiotics-12-00035-g005" position="float"/></fig><fig position="float" id="antibiotics-12-00035-f006"><label>Figure 6</label><caption><p>Structures of representative natural products that determine the biomolecular target through antibiotic resistance genes.</p></caption><graphic xlink:href="antibiotics-12-00035-g006" position="float"/></fig></floats-group></article>